Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MME | P08473 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | CPA1 | P15085 | 1/20 | 0.32 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12205309 | 0.79 | NOS3 (0.42) | SMN1; SMN2ALDH1A1MAPTFAAH | |
| SCHEMBL1348932 | 0.76 | MVD (0.32) | KDM4ETSHRACE | |
| SCHEMBL8049858 | 0.75 | MME (0.36) | SMN1; SMN2ALDH1A1MAPTFAAHKDM4E | |
| SCHEMBL16274513 | 0.74 | CRBN (0.32) | — | |
| SCHEMBL9980715 | 0.69 | ALDH1A1 (0.35) | SMN1; SMN2ALDH1A1MAPTFAAHKDM4E | |
| SCHEMBL15088189 | 0.68 | MME (0.37) | SMN1; SMN2ALDH1A1MAPTFAAHMME | |
| SCHEMBL4940723 | 0.67 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1MAPTFAAHKDM4E | |
| SCHEMBL4940730 | 0.67 | ALDH1A1 (0.44) | SMN1; SMN2ALDH1A1MAPTFAAHKDM4E | |
| SCHEMBL28571485 | 0.66 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1MAPTFAAHKDM4E | |
| SCHEMBL11312881 | 0.66 | SMN1; SMN2 (0.46) | SMN1; SMN2ALDH1A1MAPTFAAHKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9642825-B2 | Bio-available N-acetyl creatine species and compositions thereof | ENERGY BEVERAGES LLC | 2017-05-09 | — | — | US | disclosed |
| US-20150238453-A1 | BIO-AVAILABLE N-ACETYL CREATINE SPECIES AND COMPOSITIONS THEREOF | 4141 HOLDINGS, LLC (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238453-A1 | BIO-AVAILABLE N-ACETYL CREATINE SPECIES AND COMPOSITIONS THEREOF | CKMT1A; CKMT1B, RIMKLA, CRAT | SMN1; SMN2 1628/4885ALDH1A1 1179/4885MAPT 3731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.